TriangleBelinostat (NCT06406465)
Belinostat trial for Carcinoma, Neuroendocrine (NCT06406465). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–120 with high-grade neuroendocrine tumors outside the lungs, without a standard treatment known to extend life. Platinum-refractory disease is excluded.
The idea: use UGT1A1 gene variants to select intravenous belinostat doses alongside cisplatin and etoposide. Belinostat blocks HDAC enzymes, which may stop cancer cells dividing. Researchers measure drug exposure and toxicity to study dosing.
This phase 2 study plans 60 patients. Jaydira Del Rivero leads at the NIH Clinical Center in Bethesda, the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.